SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sjogren RW. Gastrointestinal motility disorders in scleroderma [review]. Arthritis Rheum 1994; 37: 126582.
  • 2
    Lock G, Holstege A, Lang B, Scholmerich J. Gastrointestinal manifestations of progressive systemic sclerosis [review]. Am J Gastroenterol 1997; 92: 76371.
  • 3
    Nietert PJ, Mitchell HC, Bolster MB, Curran MY, Tilley BC, Silver RM. Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. J Rheumatol 2005; 32: 517.
  • 4
    Gliddon AE, Dore CJ, Maddison PJ, and the QUINS Trial Study Group. Influence of clinical features on the health status of patients with limited cutaneous systemic sclerosis. Arthritis Rheum 2006; 55: 4739.
  • 5
    Khanna D. Health-related quality of life: a primer with focus on scleroderma. Scleroderma Care Res 2006; 3: 313.
  • 6
    Talley NJ, Phillips SF, Wiltgen CM, Zinsmeister AR, Melton LJ 3rd. Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc 1990; 65: 145679.
  • 7
    Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 80410.
  • 8
    Groll D, Vanner SJ, Depew WT, DaCosta LR, Simon JB, Groll A, et al. The IBS-36: a new quality of life measure for irritable bowel syndrome. Am J Gastroenterol 2002; 97: 96271.
    Direct Link:
  • 9
    US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research, US Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for Industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79.
  • 10
    Raoul JM, Verma M, Tan E, Peterson TC. Cytokines as therapeutic targets for the gastrointestinal manifestations of scleroderma. Can J Gastroenterol 2004; 18: 224.
  • 11
    Ware J, Kosinski M, Dewey J. How to score version two of the SF-36 Health Survey. Lincoln (RI): QualityMetric Incorporated; 2000.
  • 12
    Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 198491.
  • 13
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 14
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 15
    Cole JC, Khanna D, Clements PJ, Seibold JR, Tashkin DP, Paulus HE, et al. Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Qual Life Res 2006; 15: 138394.
  • 16
    Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al, for the Relaxin Study Group and the Scleroderma Clinical Trials Consortium. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005; 32: 83240.
  • 17
    Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff D, Roth MD, et al. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the Scleroderma Lung Study. Arthritis Rheum 2007; 56: 167684.
  • 18
    Hadorn DC, Hays RD. Multitrait-multimethod analysis of health-related quality-of-life measures. Med Care 1991; 29: 82940.
  • 19
    Joliffe IT, Morgan BJ. Principal component analysis and exploratory factor analysis. Stat Methods Med Res 1992; 1: 6995.
  • 20
    Shaw M, Talley NJ, Adlis S, Beebe T, Tomshine P, Healey M. Development of a digestive health status instrument: tests of scaling assumptions, structure and reliability in a primary care population. Aliment Pharmacol Ther 1998; 12: 106778.
  • 21
    Floyd F, Widaman KF. Factor analysis in the development and refinement of clinical assessment instruments. Psychol Assess 1995; 7: 28699.
  • 22
    Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297334.
  • 23
    Hays RD. Reliability and validity (including responsiveness). In: FayersP, HaysRD, editors. Assessing quality of life in clinical trials. 2nd ed. New York: Oxford; 2005. p. 2539.
  • 24
    Furst DE, Khanna D, Mattucci-Cerinic M, Silman AJ, Merkel PA, Foeldvari I, for the OMERACT 7 Special Interest Group. Scleroderma: developing measures of response. J Rheumatol 2005; 32: 247780.
  • 25
    Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006; 367: 168391.
  • 26
    Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 133: 6003.
  • 27
    Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al, and the Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 265566.
  • 28
    Steen V. Targeted therapy for systemic sclerosis [review]. Autoimmun Rev 2006; 5: 1224.
  • 29
    Khanna D, Merkel PA. Outcomes measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007; 9: 1517.
  • 30
    Best WR, Becktel JM, Singleton JW, Kern F Jr, for National Cooperative Crohn's Disease Study. Development of a Crohn's disease activity index. Gastroenterology 1976; 70: 43944.
  • 31
    Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 108894.
  • 32
    Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al, for the Anti-IL-12 Crohn's Disease Study Group. Anti-interleukin-12 antibody for active Crohn's disease [published erratum appears in N Engl J Med 2005;352:1276]. N Engl J Med 2004; 351: 206979.
  • 33
    Sjogren RW. Gastrointestinal features of scleroderma [review]. Curr Opin Rheumatol 1996; 8: 56975.
  • 34
    Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998; 93: 1605.
    Direct Link: